Dr. Jack Jacobs
Dr. Jacobs received his Ph.D. in molecular biology from the Washington University School of Medicine, St. Louis, Missouri and his B.S. in chemistry from Davidson College in North Carolina. He was recruited as an Assistant Professor to the University of Texas, San Antonio, where he established his own laboratory and received numerous awards for his research on peptide hormones, including a prestigious Research Career Development Award from the National Institutes of Health. Dr. Jacobs was recruited away from academia to Merck, where he established a Department of Biological Chemistry composed of approximately 30 researchers who focused on the discovery of new agents to inhibit blood clotting. . Dr. Jacobs then took a position as Chief Operating Officer of CardioVascular BioTherapeutics, a biotechnology company focused on the development of the FGF-1 protein in a number of clinical indications.
